Clinical Trial

Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: From Benchside to Bedside (HepAnt) - Study of the Role of the Metagenome in Head and Neck Tumors Using Omics Techniques (HeNomics).
Trial Details
NCT Number NCT06905262
Lead Sponsor National Cancer Institute, Naples
Conditions Hepatocellular Carcinoma
Enrollment 70 participants
Start Date 2023-01-02
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-01